TipRanks (Wed, 8-May 12:41 AM ET)
Arbutus to Participate in Two Upcoming Investor Conferences
Globe Newswire (Tue, 7-May 7:30 AM ET)
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 2-May 7:30 AM ET)
Globe Newswire (Thu, 2-May 7:25 AM ET)
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
Globe Newswire (Thu, 18-Apr 7:30 AM ET)
Globe Newswire (Thu, 4-Apr 8:30 AM ET)
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 29-Feb 7:30 AM ET)
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
Globe Newswire (Thu, 15-Feb 7:30 AM ET)
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
Arbutus Biopharma trades on the NASDAQ stock market under the symbol ABUS.
As of May 13, 2024, ABUS stock price was flat at $2.88 with 218,250 million shares trading.
ABUS has a beta of 0.90, meaning it tends to be less sensitive to market movements. ABUS has a correlation of 0.08 to the broad based SPY ETF.
ABUS has a market cap of $543.51 million. This is considered a Small Cap stock.
Last quarter Arbutus Biopharma reported $2 million in Revenue and -$.10 earnings per share. This fell short of revenue expectation by $-618,000 and exceeded earnings estimates by $.01.
In the last 3 years, ABUS stock traded as high as $6.50 and as low as $1.69.
The top ETF exchange traded funds that ABUS belongs to (by Net Assets): VTI, IWM, VXF, IBB, IWO.
ABUS stock has underperformed the market in the last year with a return of +9.1%, while SPY returned +27.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ABUS shares. However, ABUS has outperformed the market in the last 3 month and 2 week periods, returning +4.3% and +5.5%, while SPY returned +4.2% and +2.5%, respectively. This indicates ABUS has been having a stronger performance recently.
ABUS support price is $2.80 and resistance is $2.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABUS stock will trade within this expected range on the day.